Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

SILu^™ Lite SigmaMAb Bevacizumab Monoclonal Antibody has been used as a proangiogenic factor to study its role in the angiogenesis process by Raman spectroscopy.

Biochem/physiol Actions

Bevacizumab serves as an antitumor agent. Studies show that chemotherapy using bevacizumab improves the condition of metastatic colorectal cancer and renal cell cancer patients.

General description

SigmaMAb Bevacizumab (MSQC20) was designed to be a standard for the analysis of Bevacizumab monoclonal antibodies using mass spectrometry. An isotopically labeled version is available as SILu^™Mab Bevacizumab (MSQC21). SigmaMAb Bevacizumab is for R&D use only. Not for drug, household, or other uses.

Legal Information

SILu is a trademark of Sigma-Aldrich Co. LLC

Sequence

SigmaMab Bevacizumab Heavy Chain:EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGSigmaMab Bevacizumab Light Chain:DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC